New Neupogen Formula More Temperature Stable

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 5
Volume 6
Issue 5

THOUSAND OAKS, Calif--A new formulation of Neupogen (filgrastim or G-CSF) that contains sorbitol instead of mannitol is now available from Amgen.

THOUSAND OAKS, Calif--A new formulation of Neupogen (filgrastim or G-CSF)that contains sorbitol instead of mannitol is now available from Amgen.

The new formulation has the same clinical safety and efficacy profileas the mannitol-containing version, but offers additional flexibility withrespect to storage parameters.

Sorbitol-containing Neupogen will remain stable even if exposed to freezingtemperatures, as might occur in transit. The recommended storage temperaturewill continue to be 2° to 8° C. However, the gel tray insulationand freeze watch indicators required with mannitol-containing Neupogenwill be eliminated, allowing for smaller packaging and reduced need forrefrigerator inventory space.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content